PL3318267T3 - Środek leczniczy do leczenia zespołu huntera - Google Patents

Środek leczniczy do leczenia zespołu huntera

Info

Publication number
PL3318267T3
PL3318267T3 PL16818303T PL16818303T PL3318267T3 PL 3318267 T3 PL3318267 T3 PL 3318267T3 PL 16818303 T PL16818303 T PL 16818303T PL 16818303 T PL16818303 T PL 16818303T PL 3318267 T3 PL3318267 T3 PL 3318267T3
Authority
PL
Poland
Prior art keywords
therapeutic agent
hunter syndrome
syndrome therapeutic
hunter
agent
Prior art date
Application number
PL16818303T
Other languages
English (en)
Inventor
Jin-Kyung Lee
Han-Yeul BYUN
Myung-Eun Jung
Kyu-Hyun Lee
Original Assignee
Green Cross Corporation
Medigenebio Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corporation, Medigenebio Corporation filed Critical Green Cross Corporation
Priority claimed from PCT/KR2016/007203 external-priority patent/WO2017003270A1/ko
Publication of PL3318267T3 publication Critical patent/PL3318267T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL16818303T 2015-07-02 2016-07-04 Środek leczniczy do leczenia zespołu huntera PL3318267T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562187867P 2015-07-02 2015-07-02
KR1020150187297A KR20170004814A (ko) 2015-07-02 2015-12-28 헌터증후군 치료제
PCT/KR2016/007203 WO2017003270A1 (ko) 2015-07-02 2016-07-04 헌터증후군 치료제 및 치료방법
EP16818303.6A EP3318267B1 (en) 2015-07-02 2016-07-04 Hunter syndrome therapeutic agent

Publications (1)

Publication Number Publication Date
PL3318267T3 true PL3318267T3 (pl) 2021-07-12

Family

ID=57833331

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16818303T PL3318267T3 (pl) 2015-07-02 2016-07-04 Środek leczniczy do leczenia zespołu huntera

Country Status (14)

Country Link
US (2) US10561713B2 (pl)
EP (1) EP3318267B1 (pl)
JP (2) JP6606199B2 (pl)
KR (3) KR20170004814A (pl)
CN (1) CN107921091A (pl)
CA (1) CA2990370C (pl)
CL (1) CL2018000002A1 (pl)
CO (1) CO2018000196A2 (pl)
EA (1) EA038110B1 (pl)
ES (1) ES2866957T3 (pl)
HK (1) HK1252663A1 (pl)
MX (1) MX379982B (pl)
PE (1) PE20190351A1 (pl)
PL (1) PL3318267T3 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2716136C2 (ru) 2015-07-02 2020-03-06 Ф. Хоффманн-Ля Рош Аг Бициклические лактамы и способы их применения
JP7349359B2 (ja) 2016-10-17 2023-09-22 エフ. ホフマン-ラ ロシュ アーゲー 二環式ピリドンラクタム及びその使用方法。
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
EP3781571B1 (en) 2018-04-20 2024-01-17 F. Hoffmann-La Roche AG N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
KR102671857B1 (ko) 2018-05-30 2024-06-04 주식회사 녹십자 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물
WO2020077235A1 (en) * 2018-10-11 2020-04-16 Indivior Uk Limited Buprenorphine to treat respiratory depression
CA3106693A1 (en) * 2019-02-06 2020-08-13 Sangamo Therapeutics, Inc. Method for the treatment of mucopolysaccharidosis type i
WO2021256579A1 (ko) 2020-06-16 2021-12-23 노벨파마 주식회사 글루타르산뇨증 치료용 조성물 및 이의 투여방법
WO2024144003A1 (ko) * 2022-12-29 2024-07-04 주식회사 녹십자 뮤코다당질 축적증에서의 안면 이형의 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102439044B (zh) 2009-04-22 2014-08-13 阿特根公司 通过体内持续释放维持的体内半衰期增加的融合蛋白质或融合肽以及使用所述融合蛋白质或融合肽增加体内半衰期的方法
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
KR20130043165A (ko) * 2010-06-25 2013-04-29 샤이어 휴먼 지네틱 테라피즈 인크. 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들
CA2803166C (en) * 2010-06-25 2023-03-07 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US9682129B2 (en) 2011-12-23 2017-06-20 Shire Human Genetic Therapies, Inc. Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
BR112014024358A8 (pt) * 2012-03-30 2018-01-23 Shire Human Genetic Therapies administração subcutânea de iduronato-2-sulfatase
JP2015013624A (ja) * 2013-07-08 2015-01-22 船井電機株式会社 手動推進器具

Also Published As

Publication number Publication date
MX2017016302A (es) 2018-03-23
EA201890182A1 (ru) 2018-06-29
US10561713B2 (en) 2020-02-18
JP6858231B2 (ja) 2021-04-14
CL2018000002A1 (es) 2018-06-29
HK1252663A1 (zh) 2019-05-31
JP2020019775A (ja) 2020-02-06
EP3318267A4 (en) 2019-02-27
US20180303914A1 (en) 2018-10-25
CA2990370A1 (en) 2017-01-05
PE20190351A1 (es) 2019-03-07
CO2018000196A2 (es) 2018-03-28
EA038110B1 (ru) 2021-07-07
EP3318267B1 (en) 2021-02-24
CA2990370C (en) 2022-05-17
BR112018000051A2 (pt) 2018-09-04
KR20170004814A (ko) 2017-01-11
JP6606199B2 (ja) 2019-11-13
KR20180015256A (ko) 2018-02-12
JP2018519326A (ja) 2018-07-19
EP3318267A1 (en) 2018-05-09
ES2866957T3 (es) 2021-10-20
MX379982B (es) 2025-03-11
US20200093899A1 (en) 2020-03-26
KR102213055B1 (ko) 2021-02-08
KR20190141026A (ko) 2019-12-20
CN107921091A (zh) 2018-04-17

Similar Documents

Publication Publication Date Title
IL250685A0 (en) Medicinal substance induces cytotoxicity
SG10201912416QA (en) Therapeutic agents
GB201515650D0 (en) Medicament delivery devices
GB201509893D0 (en) Therapeutic agents
GB201516442D0 (en) Combination therapy
GB201517263D0 (en) Therapeutic agents
IL257976A (en) Combined treatment
ZA201804155B (en) Combination therapy
GB201509885D0 (en) Therapeutic agents
SG10201912684TA (en) Therapeutic agent for fibrosis
GB201502412D0 (en) Therapeutic use
GB201509888D0 (en) Therapeutic agents
IL250160A0 (en) medicinal substance
GB201513299D0 (en) Therapeutic agents
HUE066511T2 (hu) Készítmények hunter-szindróma kezelésére
GB201516153D0 (en) Chewable medicament
GB201521767D0 (en) Therapeutic agents
GB201517264D0 (en) Therapeutic agents
GB201506786D0 (en) Therapeutic use
GB201911521D0 (en) Therapeutic agent
GB201516109D0 (en) Therapeutic agent
PT3290048T (pt) Agente indutor de imunidade
GB201702921D0 (en) Therapeutic agent
PT3326626T (pt) Agente para o tratamento de dermatomicose contendo citrato tripotássico
GB201504142D0 (en) Option administration